Obesity and Altered Aspirin Pharmacology

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Metabolic Disorders

Background:

• Obesity is a significant independent risk factor for cardiovascular morbidity and mortality.
• Obesity is associated with a pro-thrombotic state, including impaired fibrinolysis and platelet hyper-reactivity.
• This pro-thrombotic state arises from interconnected factors like insulin resistance, inflammation, oxidative stress, and endothelial dysfunction.

Purpose of the Study:

• To investigate the mechanisms behind reduced aspirin pharmacodynamic response in obese individuals.
• To explore how obesity-related inflammation and metabolic endotoxemia impact antiplatelet therapy effectiveness.
• To identify pathways contributing to high on-aspirin platelet reactivity in obesity.

Main Methods:

• The study reviews existing literature on obesity, atherothrombosis, and aspirin pharmacodynamics.
• It analyzes mechanisms linking obesity's metabolic and inflammatory features to platelet function.
• Focus is placed on factors affecting aspirin bioavailability and platelet turnover.

Main Results:

• Obesity is linked to reduced aspirin pharmacodynamic response.
• Inflammatory states in obesity, such as metabolic endotoxemia, increase platelet reactivity and turnover.
• These factors can decrease aspirin bioavailability, contributing to a poor response.

Conclusions:

• Obesity significantly impairs the effectiveness of aspirin as an antiplatelet therapy.
• Understanding obesity-related mechanisms of high on-aspirin platelet reactivity is crucial.
• Optimizing antithrombotic therapy for obese patients requires addressing these specific challenges.